000			03624nam a22004937a 4500
008			141002s20142014 xxu||||| |||| 00| 0 eng d
022			_a0315-162X
040			_aOvid MEDLINE(R)
099			_a24293577
245			_aClinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort.
251			_aJournal of Rheumatology. 41(1):106-12, 2014 Jan.
252			_aJ Rheumatol. 41(1):106-12, 2014 Jan.
253			_aThe Journal of rheumatology
266			_d2014-10-02
501			_aAvailable online from MWHC library: 2001 - present
520			_aCONCLUSION: Our results suggest demographic and clinical features are sufficient to define the pansclerotic subtype as they represent a distinct clinical phenotype with a more rapidly progressive and severe course commonly accompanied by disability. Presence of features of the pansclerotic phenotype should alert practitioners to the possibility of significant morbidity and the need for early aggressive treatment.
520			_aMETHODS: Patients who met predefined criteria for generalized and pansclerotic morphea were identified using a modified Laxer and Zulian classification system. Baseline demographic and clinical features of the patients were compiled and then analyzed for traits characteristic of pansclerotic morphea versus those of generalized morphea. One hundred and thirteen patients met the criteria for inclusion: pansclerotic (n = 13) and generalized morphea type (n = 100).
520			_aOBJECTIVE: Pansclerotic morphea is a poorly described form of morphea with little information on prevalence, demographics, and clinical features. Classification criteria for this subtype varies and the distinction from other forms of morphea, such as extensive generalized morphea and pansclerotic morphea, is not always clear. The purpose of our study was to clarify classification criteria for pansclerotic morphea by identifying its prevalence in the morphea in adults and children (MAC) cohort and describing its demographic and clinical features as compared with generalized morphea.
520			_aRESULTS: Patients with pansclerotic morphea were more frequently male (46.2% vs 6%; p < 0.0001); had a shorter time to diagnosis (mean difference of 10.4 mos; 95% CI: 0.8-19.9 mos; p = 0.0332); higher rates of functional impairment (61.5% vs 16%; p = 0.0046); higher rates of deep involvement (61.5% vs 17%; p = 0.004); and higher average Rodnan Skin Score (mean difference of 10.8 points; 95% CI: 5-16.6; p = 0.0017), Localized Scleroderma Skin Damage Index (mean difference 28.3; 95% CI: 9-47.6; p = 0.009), and Physician Global Assessment of Disease Damage scores (mean difference 25.1; 95% CI: 0.3-50; p = 0.048).
546			_aEnglish
650			_a*Scleroderma, Localized/di [Diagnosis]
650			_aAdult
650			_aAged
650			_aChild
650			_aCross-Sectional Studies
650			_aDisabled Persons
650			_aFemale
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aRegistries
650			_aSeverity of Illness Index
650			_aSex Factors
650			_aTime Factors
650			_aYoung Adult
651			_aMedStar Washington Hospital Center
656			_aDermatology
657			_aJournal Article
657			_aResearch Support, N.I.H., Extramural
700			_aMarinkovich, Nicholas
790			_aJacobe HT, Kim A, Marinkovich N, Vasquez R
856			_uhttp://dx.doi.org/10.3899/jrheum.130029 _zhttp://dx.doi.org/10.3899/jrheum.130029
942			_cART _dJournal article
999			_c12263 _d12263